Apogee Therapeutics (NASDAQ:APGE) CEO Michael Thomas Henderson Sells 40,000 Shares of Stock

by · The Cerbat Gem

Apogee Therapeutics Inc. (NASDAQ:APGE – Get Free Report) CEO Michael Thomas Henderson sold 40,000 shares of the firm’s stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $75.01, for a total value of $3,000,400.00. Following the transaction, the chief executive officer directly owned 1,232,987 shares of the company’s stock, valued at approximately $92,486,354.87. This represents a 3.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Michael Thomas Henderson also recently made the following trade(s):

  • On Thursday, November 13th, Michael Thomas Henderson sold 20,000 shares of Apogee Therapeutics stock. The shares were sold at an average price of $63.01, for a total value of $1,260,200.00.

Apogee Therapeutics Price Performance

Shares of APGE opened at $76.75 on Friday. The business has a 50-day moving average of $57.59 and a 200-day moving average of $45.43. The company has a market capitalization of $5.24 billion, a price-to-earnings ratio of -17.52 and a beta of 1.41. Apogee Therapeutics Inc. has a 1 year low of $26.20 and a 1 year high of $77.09.

Apogee Therapeutics (NASDAQ:APGE – Get Free Report) last announced its earnings results on Monday, November 10th. The company reported ($1.11) EPS for the quarter, beating the consensus estimate of ($1.14) by $0.03. As a group, sell-side analysts anticipate that Apogee Therapeutics Inc. will post -3.09 EPS for the current year.

Institutional Trading of Apogee Therapeutics

Several large investors have recently made changes to their positions in APGE. Lisanti Capital Growth LLC bought a new position in Apogee Therapeutics during the second quarter valued at $800,000. Fox Run Management L.L.C. bought a new stake in shares of Apogee Therapeutics in the second quarter valued at $437,000. Allspring Global Investments Holdings LLC bought a new stake in shares of Apogee Therapeutics in the second quarter valued at $218,000. Prudential Financial Inc. lifted its position in shares of Apogee Therapeutics by 176.4% during the 2nd quarter. Prudential Financial Inc. now owns 68,845 shares of the company’s stock valued at $2,990,000 after buying an additional 43,940 shares during the last quarter. Finally, Woodline Partners LP grew its stake in shares of Apogee Therapeutics by 4.5% during the 1st quarter. Woodline Partners LP now owns 1,061,053 shares of the company’s stock worth $39,641,000 after acquiring an additional 45,445 shares during the period. 79.04% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

APGE has been the topic of several recent analyst reports. Bank of America boosted their target price on shares of Apogee Therapeutics from $78.00 to $87.00 and gave the company a “buy” rating in a report on Thursday, August 28th. Mizuho initiated coverage on Apogee Therapeutics in a research report on Tuesday, October 21st. They issued an “outperform” rating and a $105.00 price objective for the company. Wedbush reissued an “outperform” rating and issued a $90.00 price objective on shares of Apogee Therapeutics in a research note on Monday, August 11th. Wall Street Zen cut Apogee Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, Zacks Research downgraded Apogee Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $98.38.

Check Out Our Latest Report on APGE

Apogee Therapeutics Company Profile

(Get Free Report)

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.

Recommended Stories